Key result
NOACs show no greater risk than VKAs during invasive dental procedures, making suspension unnecessary.
Why the study?
Do new oral anticoagulants pose greater risks than conventional oral anticoagulants during invasive dental treatment?
Population
Patients receiving new oral anticoagulants (dabigatran, rivaroxaban, apixaban) undergoing dental care
Comparison
New oral anticoagulants vs Conventional oral anticoagulants
Design
Systematic_review
Authors
Loading...
Supports continuing NOACs without routine suspension for invasive dental procedures; confirms safety equivalence to conventional agents in Level 1 evidence.
Do new oral anticoagulants pose greater risks than conventional oral anticoagulants during invasive dental treatment?
New oral anticoagulants do not require routine suspension prior to invasive dental procedures, similar to conventional vitamin K antagonists.
Mingarro-de-Leon et al. (2013) conducted a review in Patients receiving oral anticoagulants requiring dental care. New oral anticoagulants (dabigatran, rivaroxaban, apixaban) vs. Vitamin K antagonists was evaluated. New oral anticoagulants do not pose significantly greater risks than conventional oral anticoagulants during invasive dental treatment, and their suspension is not strictly required.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: